Non-Small Cell Lung Cancer
Conditions
Keywords
BR790, Anlotinib, NSCLC, PTPN11, SHP2
Brief summary
This is a Phase Ⅰ/Ⅱa, multi-center, open-label study, aiming to evaluate the safety, tolerability, pharmacokinetic (PK), and efficacy of BR790 in combination with anlotinib in adult participants with advanced NSCLC.
Detailed description
This study is a Phase Ⅰ/Ⅱa, multi-center, open-label study of BR790 in combination with anlotinib with a dose escalation part followed by a dose expansion part in adult subjects with advanced NSCLC. Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.
Interventions
DRUGBR790+anlotinib
BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
Sponsors
Shanghai Gopherwood Biotech Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥18 and ≤75 years old. * Subjects with histologically or cytologically confirmed locally advanced or relapsed metastatic driver negative (EGFR, ALK, ROS, etc.) advanced NSCLC，whose disease progressed after at least 2 previous standard therapies. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) .
Exclusion criteria
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has uncontrolled moderate to massive effusion. * Central lung squamous carcinoma along with cavum, or non-small cell lung cancer along with hemoptysis (\>50ml/day). * Other kinds of malignancies within 5 years or for now. * Has not enough organ functional reserve at baseline, which met at least one of the following criteria： ANC\<1.5×10\^9/L, PLT\<100×10\^9/L, Hb\<100g/L; TBIL\>1.5×ULN, ALT or AST\>2.5×ULN (without liver metastases) , ALT or AST\>5×ULN (with liver metastases);Cr \>1.5×ULN, urine protein≥++，or confirmed 24h urine protein≥1.0g;INR \>1.5×ULN, PT\>1.5ULN or APTT \>1.5×ULN. * Previous use of other SHP2 inhibitors (such as TNO-155, JAB-3312, JAB-3068, RLY-1971, RMC-4630, etc.) * Has used anlotinib before * The first assessment of efficacy was PD, or occurred ≥grade 3 adverse reactions with antitumor angiogenesis small-molecule drugs (e.g. Apatinib, surufatinib, fruquintinib, etc.), or less than 6 months after the last antitumor vascular therapy. * Has got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (5.0), alopecia and grade 2 peripheral neuropathy are not included.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose/Recommended Phase Ⅱ Dose(MTD/RP2D) | 2 years | To evaluate the MTD/RP2D of BR790 in combination with anlotinib (Part 1) |
| Objective Response Rate (ORR) | 2 years | To evaluate the objective response rate (ORR) of BR790 in combination with anlotinib. ORR is defined as the proportion of subjects who achieve a Complete Response (CR) or Partial Response (PR) as assessed by RECIST v1.1 (Part 2) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate(DCR) | 2 years | DCR is defined as the proportion of subjects who achieve a Complete Response (CR) 、Partial Response (PR) or Stable Disease (SD) as assessed by RECIST v1.1 |
| Overall Survival (OS) | 2 years | OS is defined as the time from study treatment initiation to death from any cause or last day known to be alive. |
| Progression-Free Survival (PFS) | 2 years | PFS was defined as the time from randomization to documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or death due to any cause, whichever occurred first. |
| Area under the plasma concentration-time curve (AUC) | 2 years | Area under the plasma concentration time curve of BR790/anlotinib |
| Plasma concentration (Cmax) | 2 years | Highest observed plasma concentration of BR790/anlotinib |
| Adverse Events(AEs) | 2 years | Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values and vital signs for combination therapy |
| Duration of overall response (DOR) | 2 years | DOR is defined as the time from the first documented CR or PR per RECIST v1.1 to disease recurrence or disease progression (PD) whichever occurs first. |
Contacts
Primary ContactBaohui Han, professor
Outcome results
None listed